CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release
Death ligands such as CD95 ligand (CD95L) or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) induce apoptosis in radiochemotherapy-resistant human malignant glioma cell lines. The death-signaling TRAIL receptors 2 (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/DR4 we...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 July 2001
|
| In: |
Oncogene
Year: 2001, Jahrgang: 20, Heft: 31, Pages: 4128-4137 |
| ISSN: | 1476-5594 |
| DOI: | 10.1038/sj.onc.1204534 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/sj.onc.1204534 Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/1204534 
|
| Verfasserangaben: | Till A. Röhn, Bettina Wagenknecht, Wilfried Roth, Ulrike Naumann, Erich Gulbins, Peter H. Krammer, Henning Walczak and Michael Weller |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1755431406 | ||
| 003 | DE-627 | ||
| 005 | 20230427042535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210420s2001 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/sj.onc.1204534 |2 doi | |
| 035 | |a (DE-627)1755431406 | ||
| 035 | |a (DE-599)KXP1755431406 | ||
| 035 | |a (OCoLC)1341405021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Röhn, Till Alexander |d 1974- |e VerfasserIn |0 (DE-588)129024767 |0 (DE-627)387777636 |0 (DE-576)187869200 |4 aut | |
| 245 | 1 | 0 | |a CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release |c Till A. Röhn, Bettina Wagenknecht, Wilfried Roth, Ulrike Naumann, Erich Gulbins, Peter H. Krammer, Henning Walczak and Michael Weller |
| 264 | 1 | |c 17 July 2001 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 20.04.2021 | ||
| 520 | |a Death ligands such as CD95 ligand (CD95L) or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) induce apoptosis in radiochemotherapy-resistant human malignant glioma cell lines. The death-signaling TRAIL receptors 2 (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/DR4 were expressed more abundantly than the non-death-inducing (decoy) receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 in 12 human glioma cell lines. Four of the 12 cell lines were TRAIL/Apo2L-sensitive in the absence of a protein synthesis inhibitor, cycloheximide (CHX). Three of the 12 cell lines were still TRAIL/Apo2L-resistant in the presence of CHX. TRAIL-R2 expression predicted sensitivity to apoptosis. Coexposure to TRAIL/Apo2L and cytotoxic drugs such as topotecan, lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, CCNU) or temozolomide resulted in synergistic killing. Synergistic killing was more often observed in cell lines retaining wild-type p53 activity (U87MG, LN-229) than in p53 mutant cell lines (LN-18, T98G, U373MG). Drug exposure resulted in enhanced TRAIL-R2 expression, but decreased TRAIL-R4 expression in U87MG cells. Ectopic expression of dominant-negative p53V135A abrogated the drug-induced changes in TRAIL-R2 and TRAIL-R4 expression, but had no effect on synergy. Thus, neither wild-type p53 function nor changes in TRAIL receptor expression were required for synergy. In contrast, synergy resulted possibly from drug-induced cytochrome c release from mitochondria, serving as an amplifier of the TRAIL/Apo2L-mediated cascade of caspase activation. These data provide novel insights into the role of the TRAIL/Apo2L system in malignant gliomas and illustrate that TRAIL/Apo2L-based immunochemotherapy may be an effective therapeutic strategy for these lethal neoplasms. | ||
| 700 | 1 | |a Krammer, Peter H. |d 1946- |e VerfasserIn |0 (DE-588)121766373 |0 (DE-627)081520255 |0 (DE-576)292873417 |4 aut | |
| 700 | 1 | |a Walczak, Henning |d 1966- |e VerfasserIn |0 (DE-588)172932513 |0 (DE-627)697859703 |0 (DE-576)133786773 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncogene |d London : Springer Nature, 1997 |g 20(2001), 31, Seite 4128-4137 |h Online-Ressource |w (DE-627)320469964 |w (DE-600)2008404-3 |w (DE-576)096188715 |x 1476-5594 |7 nnas |a CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release |
| 773 | 1 | 8 | |g volume:20 |g year:2001 |g number:31 |g pages:4128-4137 |g extent:10 |a CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release |
| 856 | 4 | 0 | |u https://doi.org/10.1038/sj.onc.1204534 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/1204534 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210420 | ||
| 993 | |a Article | ||
| 994 | |a 2001 | ||
| 998 | |g 172932513 |a Walczak, Henning |m 172932513:Walczak, Henning |d 50000 |e 50000PW172932513 |k 0/50000/ |p 7 | ||
| 998 | |g 121766373 |a Krammer, Peter H. |m 121766373:Krammer, Peter H. |d 50000 |e 50000PK121766373 |k 0/50000/ |p 6 | ||
| 999 | |a KXP-PPN1755431406 |e 3913820027 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1755431406","language":["eng"],"note":["Gesehen am 20.04.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Till Alexander","family":"Röhn","role":"aut","display":"Röhn, Till Alexander","roleDisplay":"VerfasserIn"},{"family":"Krammer","given":"Peter H.","roleDisplay":"VerfasserIn","display":"Krammer, Peter H.","role":"aut"},{"given":"Henning","family":"Walczak","role":"aut","display":"Walczak, Henning","roleDisplay":"VerfasserIn"}],"title":[{"title":"CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release","title_sort":"CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release"}],"relHost":[{"id":{"eki":["320469964"],"zdb":["2008404-3"],"issn":["1476-5594"]},"origin":[{"dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Nature Publ. Group","publisherPlace":"London ; Basingstoke"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Oncogene","subtitle":"including Oncogene reviews","title_sort":"Oncogene"}],"part":{"text":"20(2001), 31, Seite 4128-4137","volume":"20","extent":"10","year":"2001","pages":"4128-4137","issue":"31"},"pubHistory":["Nachgewiesen 14.1997 -"],"language":["eng"],"recId":"320469964","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 18.03.05"],"disp":"CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c releaseOncogene"}],"physDesc":[{"extent":"10 S."}],"name":{"displayForm":["Till A. Röhn, Bettina Wagenknecht, Wilfried Roth, Ulrike Naumann, Erich Gulbins, Peter H. Krammer, Henning Walczak and Michael Weller"]},"id":{"eki":["1755431406"],"doi":["10.1038/sj.onc.1204534"]},"origin":[{"dateIssuedKey":"2001","dateIssuedDisp":"17 July 2001"}]} | ||
| SRT | |a ROEHNTILLACCNUDEPEND1720 | ||